No Data
No Data
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $52
Express News | PTC Therapeutics Inc : Leerink Partners Raises Target Price to $52 From $50
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC and Jazz Pharmaceuticals Among Latest Firms to Win EU Backing for Drugs
Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Amid European and U.S. Approval Prospects for Sephience
Express News | RPT-EMA Says Chmp Recommended Granting Conditional Marketing Authorisation for Ziihera (Zanidatamab)